A single dose of the immunosuppressant drug rapamycin temporarily reversed autism-like brain dysfunction and behavioral traits in adult mice within two hours, according to a study published in Nature Communications. The research, conducted by scientists at UCLA Health, demonstrated that inflammation during pregnancy can lead to persistent brain and behavioral changes in offspring, which were significantly improved by rapamycin treatment. The findings suggest new therapeutic targets for autism-related symptoms, though the effects were temporary and the drug’s long-term safety remains uncertain.
Study Shows Rapid Reversal of Autism-Like Symptoms in Mice
Methodology and Experimental Setup
The study involved exposing pregnant mice to a mild inflammatory stimulus, which induced autism-like behaviors in their offspring, including abnormal brain growth, seizures, and heightened sensory sensitivity. Researchers then administered a single dose of rapamycin to adult mice exhibiting these traits. Within two hours, the drug improved brain signaling, reduced repetitive behaviors, and normalized sensory responses. The effects were observed across nearly all measured domains, including neuronal activity, seizure susceptibility, and interbrain region communication.
The experimental framework used a parallel group design, with control and MIR (maternal inflammation) groups. Mice were tested at young adult (P60-90) and old adult (P200-400) stages, with some animals retaining the MIR phenotype for longitudinal analysis. The study adhered to ARRIVE 2.0 guidelines, ensuring methodological rigor. No animal exclusions were necessary, as the outbred CD1 mouse strain allowed for a range of phenotype severities.
Mechanism of Action and Limitations
Rapamycin, an mTOR inhibitor, works by modulating cellular processes like growth and metabolism. The study found that the drug’s rapid effects stemmed from altering brain function rather than repairing structural damage. Gene expression analysis revealed that rapamycin reversed abnormal patterns linked to autism and epilepsy, particularly in excitatory neurons. However, the benefits were short-lived, with symptoms returning after 72 hours. Mice also developed tolerance to the drug after weeks of repeated exposure, diminishing its effectiveness.
Researchers emphasized that rapamycin is not a viable treatment for autism due to its toxicity, temporary effects, and lack of long-term efficacy. This points toward new therapeutic targets like sensory circuit neuromodulation or balancing neuronal inhibition and excitation, rather than toward rapamycin itself as a treatment,
said co-senior author Dr. Neil Harris, a UCLA neurosurgery professor.
Implications for Autism Research
The study challenges assumptions about the adult brain’s adaptability, suggesting that functional normalization of autism-like symptoms may be achievable without correcting underlying structural changes. The level of functional normalization achieved over this short time suggests new mechanisms by which possible treatments may act,
said senior author Dr. Harley Kornblum, director of the UCLA Intellectual and Developmental Disabilities Research Center. The findings highlight the mTOR pathway as a potential target for therapies addressing sensory overresponsivity and other persistent autism traits.
While the results offer hope for future treatments, the researchers stressed that human trials are not imminent. The study’s focus on mouse models and the drug’s limitations underscore the need for further investigation into safer, more sustainable interventions. This points us toward the brain’s functional circuitry, not just its physical structure, as a target for future treatment approaches,
added first author Dr. Janel Le Belle, an associate professor at UCLA.
Keep reading
